Tarceva Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Alerts
• Clinical Trials

To Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Condition:   Non-small Cell Lung Cancer Interventions:   Biological: 30 μg OBI-833/100 μg OBI-821;   Drug: Erlotinib (150 mg daily) Sponsor:   OBI Pharma, Inc Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 1, 2022 Category: Research Source Type: clinical trials

Brazilian Lung Immunotherapy Study
Condition:   Lung Neoplasm Interventions:   Drug: Alectinib;   Drug: Pembrolizumab;   Drug: Nivolumab;   Drug: Erlotinib Sponsors:   Hospital Israelita Albert Einstein;   Ministry of Health, Brazil Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 18, 2021 Category: Research Source Type: clinical trials